Publicaciones en las que colabora con Jesús María Prieto Valtueña (37)

2018

  1. TMEM173 Alternative Spliced Isoforms Modulate Viral Replication through the STING Pathway

    ImmunoHorizons, Vol. 2, Núm. 11, pp. 363-376

2016

  1. A versatile vector for in vivo monitoring of type I interferon induction and signaling

    PLoS ONE, Vol. 11, Núm. 3

  2. Gene expression analysis during acute hepatitis C virus infection associates dendritic cell activation with viral clearance

    Journal of Medical Virology, Vol. 88, Núm. 5, pp. 843-851

  3. Interferon alpha bioactivity critically depends on Scavenger receptor class B type I function

    OncoImmunology, Vol. 5, Núm. 8

2015

  1. A RIG-I 2CARD-MAVS200 Chimeric Protein Reconstitutes IFN-β Induction and Antiviral Response in Models Deficient in Type i IFN Response

    Journal of Innate Immunity, Vol. 7, pp. 466-481

  2. Clinical testing of a dendritic cell targeted therapeutic vaccine in patients with chronic hepatitis C virus infection

    Molecular Therapy - Methods and Clinical Development, Vol. 2, pp. 15006

  3. Enhanced therapeutic effect using sequential administration of antigenically distinct oncolytic viruses expressing oncostatin M in a Syrian hamster orthotopic pancreatic cancer model

    Molecular Cancer, Vol. 14, Núm. 1

2014

  1. A quick and efficient method to generate mammalian stable cell lines based on a novel inducible alphavirus DNA/RNA layered system

    Cellular and Molecular Life Sciences, Vol. 71, Núm. 23, pp. 4637-4651

  2. Characterization of the CD40L/Oncostatin M/Oncostatin M receptor axis as an antiviral and immunostimulatory system disrupted in chronic HCV infection

    Journal of Hepatology, Vol. 60, Núm. 3, pp. 482-489

  3. Dysregulation of interferon regulatory factors impairs the expression of immunostimulatory molecules in hepatitis C virus genotype 1-infected hepatocytes

    Gut, Vol. 63, Núm. 4, pp. 665-673

2013

  1. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C

    Journal of Hepatology, Vol. 59, Núm. 1, pp. 81-88

  2. Usage of Adenovirus Expressing Thymidine Kinase Mediated Hepatocellular Damage for Enabling Mouse Liver Repopulation with Allogenic or Xenogenic Hepatocytes

    PLoS ONE, Vol. 8, Núm. 9

2012

  1. CD8 T cell priming in the presence of IFN-α renders CTLs with improved responsiveness to homeostatic cytokines and recall antigens: important traits for adoptive T cell therapy

    Journal of Immunology, Vol. 189, Núm. 7, pp. 3299-3310

  2. Modulation of regulatory T-cell activity in combination with interleukin-12 increases hepatic tolerogenicity in woodchucks with chronic hepatitis B

    Hepatology, Vol. 56, Núm. 2, pp. 474-483

  3. N-terminal acetylome analyses and functional insights of the N-terminal acetyltransferase NatB

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 109, Núm. 31, pp. 12449-12454

2011

  1. Anchoring interferon alpha to apolipoprotein A-I reduces hematological toxicity while enhancing immunostimulatory properties

    Hepatology, Vol. 53, Núm. 6, pp. 1864-1873

  2. Cardiotrophin-1 promotes a high survival rate in rabbits with lethal fulminant hepatitis of viral origin

    Journal of Virology, Vol. 85, Núm. 24, pp. 13124-13132

  3. Hepatitis C virus induces the expression of CCL17 and CCL22 chemokines that attract regulatory T cells to the site of infection

    Journal of Hepatology, Vol. 54, Núm. 3, pp. 422-431

  4. Improved dendritic cell-based immunization against hepatitis C virus using peptide inhibitors of interleukin 10

    Hepatology, Vol. 53, Núm. 1, pp. 23-31

2010

  1. Effects of IFN-α as a signal-3 cytokine on human naïve and antigen-experienced CD8+ T cells

    European Journal of Immunology, Vol. 40, Núm. 12, pp. 3389-3402